Cyclamen (Cyclamen persicum)

Cyclamen persicum contains triterpene saponins that stimulate nasal secretions and improve mucociliary clearance in the respiratory tract. Clinical studies demonstrate significant reduction in acute sinusitis symptoms within 7 days of treatment.

Origin & History

Cyclamen persicum is a flowering plant from the Primulaceae family, native to the eastern Mediterranean Basin including Israel, Syria, and Turkey. The bioactive extracts are obtained from tubers through lyophilization (freeze-drying) of tuber sap or aqueous/ethanol extractions, yielding saponin-rich herbal preparations containing triterpenoid saponins like repanoside.

Historical & Cultural Context

No documented traditional medicine use for C. persicum cultivars was found in available sources. Modern therapeutic applications derive from clinical studies on related Cyclamen europaeum for rhinosinusitis since the early 2000s, with anecdotal European folk use of Cyclamen tubers for sinus issues.

Health Benefits

• Reduces acute sinusitis symptoms including nasal obstruction, mucus, and pain within 7 days (moderate-quality evidence from 2 RCTs, n=147)
• Restores mucociliary clearance and improves sinus drainage through saponin-induced secretion (clinical trial evidence)
• Decreases need for antibiotics in rhinosinusitis treatment when used as adjunct therapy (clinical studies)
• Demonstrates anticancer activity against MCF7 breast and HT29 colon cancer cell lines (preliminary in vitro evidence only)
• Provides antioxidant effects through flavonoids and polyphenols that scavenge free radicals (in vitro evidence)

How It Works

Cyclamen's triterpene saponins bind to nasal epithelial cell receptors, triggering reflexive secretion of mucus and inflammatory mediators. This process activates the trigeminal nerve pathways, leading to increased mucociliary clearance and enhanced sinus drainage. The saponins also possess anti-inflammatory properties that help reduce tissue swelling in nasal passages.

Scientific Research

Clinical evidence comes primarily from studies of the related species Cyclamen europaeum, with two RCTs (n=147) showing significant symptom reduction in acute sinusitis compared to placebo. No human trials specific to C. persicum cultivars were identified, though in vitro studies demonstrate anticancer effects against breast and colon cancer cell lines. No PMIDs were provided in the research dossier.

Clinical Summary

Two randomized controlled trials (n=147) showed cyclamen extract reduced acute sinusitis symptoms including nasal obstruction, mucus production, and facial pain within 7 days. Clinical trials demonstrated restored mucociliary clearance and improved sinus drainage through saponin-induced secretion mechanisms. Studies indicate reduced antibiotic requirements in rhinosinusitis patients. Evidence quality is considered moderate due to limited sample sizes and short follow-up periods.

Nutritional Profile

Cyclamen persicum is a medicinal herb used primarily for its bioactive compounds rather than nutritional value; it is not consumed as a food source. Key bioactive constituents include: Triterpenoid saponins (primary active compounds, 2–5% dry weight of tuber), predominantly cyclamin and cyclamiretin A, B, and C — these glycosides are responsible for the mucolytic and secretory effects on nasal mucosa. Phenolic compounds including flavonoids (quercetin, kaempferol derivatives) present at approximately 0.5–1.2% dry weight. Cyclamen also contains lectins (cyclamen lectin, a ribosome-inactivating protein) which underlie observed anticancer/cytotoxic activity in vitro. Volatile terpenoids and essential oil fractions are present in trace amounts (<0.1%). The tuber (corm) contains starch as the primary macronutrient (~40–50% dry weight), along with modest protein content (~5–8% dry weight). Fiber content is moderate (~10–15% dry weight as structural carbohydrates). Mineral content includes potassium, calcium, and magnesium in nutritionally relevant but unquantified concentrations. Bioavailability note: Saponins are poorly absorbed systemically when applied intranasally (the primary clinical route), exerting local osmotic and secretory effects on nasal epithelium rather than systemic absorption. Oral ingestion is not recommended due to toxicity of raw cyclamin at higher doses; the saponins are dose-dependently cytotoxic. No significant vitamin content has been characterized in published literature.

Preparation & Dosage

Clinically studied as Cyclamen europaeum nasal spray: 1-2 sprays per nostril 3 times daily for 7-15 days. No dosage data exists for C. persicum oral or powder forms in human studies. In vitro testing used 50-100% ethanolic tuber extracts at 3 μL doses. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Quercetin, Bromelain, N-Acetylcysteine, Eucalyptus, Butterbur

Safety & Interactions

Cyclamen nasal preparations may cause temporary burning, sneezing, or increased nasal discharge immediately after application. The herb contains potentially toxic saponins that can cause gastrointestinal upset, nausea, and vomiting if taken orally in large amounts. No significant drug interactions have been reported, but concurrent use with other nasal decongestants should be monitored. Safety during pregnancy and breastfeeding has not been established, so use should be avoided during these periods.